Nurosym Research: Clinical Studies Behind the Most Clinically Studied Auricular Vagus Nerve Therapy

Parasym's Clinical Research Programme

Parasym is a neurotechnology company that has developed one of the most extensive clinical research programmes in the field of non-invasive auricular vagus nerve stimulation. The company's scientific work investigates how targeted stimulation of vagal nerve branches accessible through the ear can influence multiple physiological systems, including autonomic regulation, cardiovascular function, cognitive performance, inflammation, and systemic recovery.

This research programme forms the scientific foundation behind Nurosym, Parasym's wearable neuromodulation device. Parasym has led a rigorous research agenda - designing and driving peer-reviewed clinical studies across a diverse range of patient populations and physiological domains.

The scientific evidence accumulated through this programme positions Parasym as a research-driven organisation in the emerging field of auricular vagus nerve therapy - one that distinguishes itself through the depth and breadth of its published clinical science.

Auricular Vagal Neuromodulation Technology (AVNT): The Scientific Foundation of Nurosym

Auricular Vagal Neuromodulation Technology (AVNT^TM ) is a non-invasive approach to neuromodulation that involves the targeted electrical stimulation of vagal nerve branches accessible through the external ear. The auricular branch of the vagus nerve, also referred to as Alderman's nerve or Arnold's nerve, is the only branch of the vagus nerve whose sensory fibres reach the skin's surface, making the outer ear uniquely suited to direct, non-invasive stimulation.

Because the vagus nerve serves as a primary conduit for bidirectional communication between the brain and body, stimulation of its auricular branch can engage regulatory pathways that influence a wide range of physiological systems. Research into AVNT explores how precisely delivered electrical signals to these vagal afferents travel to regulatory centres in the brainstem, particularly the nucleus tractus solitarius, and from there influence downstream networks involved in autonomic regulation, immune function, and brain-body communication.

This mechanistic breadth is why Parasym’s research programme spans multiple domains: the same anatomical pathway that influences heart rhythm also plays a role in stress regulation, inflammatory signalling, energetic and cognitive resource allocation. AVNT research, by its nature, investigates the same intervention across different physiological systems and clinical contexts.

Parasym’s proprietary AVNT represents the company’s refined approach to delivering stimulation through the ear in a way that selectively engages afferent vagal fibres, maximising vagal activation and avoiding off-target efferent side effects. This technology serves as the common platform across Parasym's clinical research and is the basis of the Nurosym device.

The Parasym Research Ecosystem

Parasym's research is conducted alongside partnerships with over 100 independent academic and medical institutions, including leading hospitals and university research centres across Europe and North America.

These collaborations include universities, teaching hospitals, and specialist clinical institutions across multiple countries. Partner institutions have included Harvard and UCLA, alongside a range of European academic and medical centres. Research has been carried out across different healthcare systems and patient populations, contributing to the cross-institutional validity of findings.

The ecosystem supports a variety of research activities: from mechanistic physiological investigations examining how auricular stimulation affects specific biomarkers, to controlled clinical trials evaluating outcomes in defined patient groups, to longer-term studies assessing sustained effects following intervention periods.

This collaborative structure is significant because it means Parasym's scientific evidence base has been generated, and in many cases, independently validated, by external investigators who have no commercial stake in the outcomes. The research reflects findings generated within independent academic and clinical settings, rather than internally produced marketing claims.

This approach benefits both the field of VNS research, by producing high-value, reproducible data, and AVNT users who are provided with evidence-based results associated with the specific device and delivery system they have in their hands.

Clinical Evidence and Published Research: Key Numbers

Parasym's research programme has resulted in a substantial body of clinical evidence. The following figures characterise the scope of the research conducted using Parasym's AVNT:

• 50+ completed clinical studies examining the physiological and clinical effects of auricular VNS

• 100+ research collaborations with academic and medical institutions worldwide

• $10M+ invested in research and development of AVNT technology

• Broad physiological domains investigated across the research programme (cardiovascular, autonomic, sleep, inflammation, cognition, stress/mood, chronic conditions, post-viral recovery)

• 10+ years of active research into auricular vagus nerve stimulation

• Diverse patient populations studied, including individuals with cardiovascular disease, POTS, chronic fatigue, post-viral syndromes, fibromyalgia, mood disorders, and healthy adult cohorts

These investigations have used validated study designs, including randomised controlled trials, sham-controlled trials, crossover studies, and longitudinal physiological investigations, providing a methodologically rigorous foundation for interpreting outcomes.

Clinical and Physiological Research Approaches

Multiple investigative approaches have been used across the research programme, each targeting different aspects of Parasym’s AVNT.

Randomised Controlled Trials

Several studies have employed randomised, sham-controlled designs, the methodological standard for evaluating clinical interventions. In these trials, active AVNT is compared against a matched placebo condition (such as earlobe stimulation or other in-built sham paradigms that do not engage vagal fibres), enabling researchers to attribute observed outcomes specifically to AVNT vagal activation.

Physiological and Biomarker Studies

A significant portion of the research programme involves mechanistic investigations that measure the physiological effects of AVNT on specific biomarkers, including heart rate variability (HRV), inflammatory cytokines, blood pressure, endothelial function, oxidative stress markers, and electrophysiological cardiac parameters. These studies help establish the biological mechanisms through which AVNT produces its effects.

Longitudinal and Follow-up Investigations

Several studies have assessed the durability of effects observed during the intervention period, measuring outcomes days, weeks, or months after active stimulation has ended. This type of investigation is important for understanding whether AVNT produces lasting changes in physiological regulation, rather than only transient responses during active use.

Population-Specific Clinical Trials

Research has also been conducted in defined clinical populations, including patients with atrial fibrillation, postural tachycardia syndrome (POTS), heart failure, Long COVID, fibromyalgia, and chronic fatigue. These condition-specific investigations examine how AVNT may influence disease-relevant outcomes within populations defined by particular autonomic or systemic dysregulation.

Research Categories: A Structured Overview

Because the vagus nerve plays a role in regulating multiple physiological systems, Parasym's research spans several distinct domains of human physiology. The following sections organise published and ongoing investigations into eight major research categories, each representing a significant area of scientific inquiry within the Parasym clinical programme.

Methodology & Publication Note Some studies referenced in this overview are available only as abstracts, conference presentations, or limited-access journal publications. As these are independent academic studies, Parasym cannot distribute full-text versions unless the journal or publisher has made them openly accessible. Percentage figures referenced throughout this overview may be derived from reported study data, including baseline-to-post changes, active versus sham comparisons, or specific biomarker and symptom-scale outcomes. These figures should be interpreted in relation to the study population, protocol, and outcome measure used. Some research paper abstracts use general terms such as “auricular vagus nerve stimulation” or “non-invasive vagus nerve stimulation” even when the study used Parasym technology. The specific device, stimulation protocol, or AVNT™ attribution is often detailed later within the full publication, particularly in the methods section.

1. Stress, Mood, and Emotional Regulation

This research domain examines how AVNT may influence psychological and emotional outcomes, including anxiety, perceived stress, depressive symptom scores, and emotional resilience. The physiological underpinning is well-established: vagal tone is closely associated with capacity for emotional regulation, and reductions in parasympathetic activity are linked to heightened anxiety and mood dysregulation.

Topics Explored

Key areas include: anxiety symptom measurement using validated scales for specific outcomes such as perceived stress responses, depressive symptom burden, emotional resilience and flexibility, as well as the neurobiological mechanisms linking vagal activation to affective regulation via brainstem-limbic pathways.

Clinical Studies

Clinical studies have assessed mood and emotional outcomes in populations including individuals with Long COVID, fibromyalgia, community-dwelling adults with subthreshold affective symptoms, and healthy volunteers participating in structured psychological training protocols.

Key findings from this area of research include:

• 35% reduction in anxiety symptoms - with moderate-to-large effect sizes in the early stimulation phase compared with sham, in community-dwelling adults with subthreshold anxiety.

• Reduction in perceived stress - with effect sizes in the moderate-to-large range during the early stimulation phase compared with the sham.

• 45% reduction in depressive symptom scores - in Long COVID patients, with improvements sustained beyond the active treatment period.

• 48% reduction in fatigue and emotional symptom burden - in Long COVID patients following AVNT.

• Enhanced self-compassion outcomes - when AVNT was combined with structured psychological training, compared with training alone.

These findings suggest that AVNT may support emotional regulatory capacity - not through sedation or suppression, but by modulating the autonomic nervous system's role in stress appraisal and affective processing.

Selected Published Research Using Parasym Technology

Jackowska, M., et al. (2025). Effects of transcutaneous vagus nerve stimulation on subthreshold affective symptoms and perceived stress. Findings from a single-blinded randomized trial.

Verbanck, P., et al. (2021). Transcutaneous Auricular Vagus Nerve Stimulation (tVNS) can Reverse the Manifestations of the Long-COVID Syndrome: A Pilot Study. Advances in Neurology and Neurosciences Research.

Kamboj, S.K., et al. (2025). Electroceutical enhancement of self-compassion training using transcutaneous vagus nerve stimulation. Psychological Medicine.

2. Chronic Fatigue and Post-Viral Recovery

This research domain investigates the application of AVNT in the context of Long COVID and other post-viral syndromes. Long COVID is characterised by persistent autonomic dysfunction, chronic fatigue, cognitive impairment, and multi-system symptom burden following SARS-CoV-2 infection, a profile that overlaps substantially with the physiological targets of the research. While anchored in post-viral research, this domain addresses autonomic and fatigue-related mechanisms that extend well beyond Long COVID.

Topics Explored

Key areas include: post-viral fatigue and energy dysregulation, autonomic dysfunction following infection, cognitive and neurological symptoms (brain fog, memory impairment, attention difficulties), mood and emotional dysregulation, sleep disruption, and the feasibility of neuromodulation as a supportive approach in post-viral populations.

Clinical Studies

Parasym's AVNT research in Long COVID populations has included pilot studies, cohort investigations, and open-label trials. Studies have assessed multiple symptom domains simultaneously, reflecting the multi-system nature of Long COVID.

Relevance Beyond Long COVID

Long COVID provided a well-characterised population in which autonomic dysfunction, reduced vagal tone, and chronic fatigue are consistently present, making it a rigorous context in which to evaluate AVNT. But the mechanisms under investigation are not unique to post-viral illness. The findings are broadly relevant to anyone experiencing autonomic imbalance or persistent fatigue, regardless of cause, including stress-related exhaustion. In this sense, the Long COVID studies serve as a model for how AVNT may support nervous system regulation wherever these pathways are disrupted.

Key findings from this area of research include:

• 57% positive response rate - in a pilot study of Long COVID and chronic fatigue patients, exceeding the pre-specified criterion for treatment success at six weeks.

• Significant improvements in cognition, anxiety, depression, and sleep quality - with medium-to-large effect sizes in a Long COVID female cohort following 10 days of treatment, with effects sustained at one month post-treatment.

• 48% reduction in fatigue scores and 45% reduction in depression scores in Long COVID patients, with improvements observed beyond the active treatment period.

• 40% improvement in digestive function - as a secondary outcome in Long COVID populations, reflecting the vagus nerve's role in gut-brain communication.

The Long COVID research cluster is particularly notable because the condition currently lacks established disease-modifying treatments. Parasym's AVNT research represents one of the few evidence-based, non-pharmacological investigational approaches with published clinical data in this population.

Selected Published Research Using Parasym Technology

Zheng, Y., et al. (2024). Transcutaneous vagus nerve stimulation improves Long COVID symptoms in a female cohort: a pilot study. Frontiers in Neurology. https://pmc.ncbi.nlm.nih.gov/articles/PMC11097097/

Verbanck, P., et al. (2021). Transcutaneous Auricular Vagus Nerve Stimulation (tVNS) can Reverse the Manifestations of the Long-COVID Syndrome: A Pilot Study.

Natelson, B., et al. (2022). Transcutaneous vagus nerve stimulation for long COVID and chronic fatigue symptoms. medRxiv.

3. Cardiovascular and Circulatory Regulation

This research domain investigates how AVNT influences cardiovascular function, including heart rhythm, blood pressure, cardiac output, and vascular health. The vagus nerve plays a central role in regulating cardiac electrophysiology through its parasympathetic innervation of the heart, making cardiovascular research a foundational area of investigation.

Topics Explored

Key scientific concepts in this domain include: atrial electrophysiology and arrhythmia susceptibility, autonomic modulation of blood pressure, endothelial function and vascular flexibility, cardiac output and ventricular mechanics, and the interplay between vagal tone and cardiovascular risk markers.

Clinical Studies

Clinical studies in this area have examined populations including patients with atrial fibrillation, heart failure, postural tachycardia syndrome, premature ventricular contractions, hypertension, and Takotsubo syndrome, as well as healthy volunteers.

Studies have explored how auricular stimulation affects heart rate variability (HRV), cardiac rhythm stability, blood pressure regulation, and endothelial function. Researchers have also examined changes in electrophysiological markers such as atrial refractory periods and atrioventricular nodal conduction - parameters that help explain why AVNT may influence arrhythmia burden.

Key findings from this area of research include:

• 85% reduction in atrial fibrillation burden - compared with sham stimulation at 6 months in a randomised clinical trial examining AF burden in patients with persistent atrial fibrillation.

• 40% reduction in postural tachycardia - compared with sham in patients with POTS at 2 months, with concurrent reductions in antiadrenergic autoantibodies and inflammatory cytokines.

• ~9.7% reduction in systolic and ~10.2% in diastolic blood pressure - over three months in young adults with Grade 1 hypertension.

• ~50% improvement in endothelial function (FMD) - and ~64% improvement in microcirculatory blood flow in heart failure patients.

• ~34% improvement in cardio-vagal baroreflex gain - in patients with chronic heart failure following right-sided auricular stimulation.

• 29% improvement in heart muscle pumping strength and efficiency - measured by left ventricular global longitudinal strain (GLS) in patients with Takotsubo syndrome.

Regarding safety, to date, a large safety analysis reported no device-related serious adverse events across a cardiovascular patient cohort, with minor tolerability issues in 1.5% of participants.

 

Selected Published Research Using Parasym Technology

Stavrakis, S., et al. (2020). TREAT AF — Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Atrial Fibrillation. JACC: Clinical Electrophysiology.

Stavrakis, S., et al. (2023). Noninvasive vagus nerve stimulation in postural tachycardia syndrome. JACC: Clinical Electrophysiology.

Dasari, T., et al. (2023). Noninvasive low-level tragus stimulation attenuates inflammation and oxidative stress in acute heart failure. Clinical Autonomic Research.

Mbikyo, E., et al. (2024). Low-Level Tragus Stimulation Attenuates Blood Pressure in Young Individuals With Hypertension. Journal of the American Heart Association.

Zafeiropoulos, S., et al. (2025). Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Premature Ventricular Contractions (NoVa-PVC). JACC: Clinical Electrophysiology.

Gentile, F., et al. (2024). Acute right-sided transcutaneous vagus nerve stimulation improves cardio-vagal baroreflex gain in patients with chronic heart failure. Clinical Autonomic Research.

Dalle Luche, R., et al. (2024). First report of safety and tolerability of low-level tragus vagal neuromodulation in cardiovascular patients. Journal of the American College of Cardiology.

Olarte, N., et al. (2024). Electrophysiological effects of transcutaneous vagal nerve stimulation in humans. AHA Circulation.

Nagai, T., et al. (2024). Vagal neuromodulation on ventricular mechanics in Takotsubo syndrome: a first-in-human proof-of-concept study. American Journal of Therapeutics.

Nagai, T., et al. (2024). Blood pressure variability after non-invasive low-level tragus stimulation in acute heart failure. Journal of Cardiovascular Translational Research.

Kharbanda, R., et al. (2023). Insights into the effects of low-level vagus nerve stimulation on atrial electrophysiology: towards patient-tailored cardiac neuromodulation. JACC: Clinical Electrophysiology, 9(9), 1843–1853.

4. Autonomic Nervous System Regulation

This domain investigates how AVNT influences the balance and function of the autonomic nervous system, specifically the balance between sympathetic ('fight-or-flight') and parasympathetic ('rest-and-digest') activity. Heart rate variability (HRV) serves as the primary objective biomarker in this research area, reflecting the degree of vagal tone and autonomic adaptability.

Topics Explored

Key scientific concepts include: parasympathetic nervous system activation, vagal tone, and HRV metrics (RMSSD, HF power, LF/HF ratio), circadian and temporal influences on vagal responsiveness, stimulation parameter optimisation (frequency, duration, laterality), and the distinction between autonomic responders and non-responders.

Clinical Studies

Studies in this domain have examined both healthy individuals and patient populations, measuring how different auricular stimulation protocols affect markers of autonomic balance. Research has explored the influence of time of day, dosing, and anatomical positioning on the magnitude of vagal response.

Key findings from this area of research include:

• 61% improvement in HRV / vagus nerve activity - average rise in vagal-tone biomarkers, including HF power, measured in double-blind, placebo-controlled studies.

• Significant increases in HRV parameters - including RMSSD, pNN50, and HF power, reflecting increased parasympathetic activity - particularly with morning stimulation compared with evening in healthy adults.

• 10 minutes of stimulation is sufficient to observe some initial effects - to induce significant improvements in vagal HRV markers in a study examining stimulation duration effects.

• ~10–20% relative improvement in HRV - with Parasym’s optimised AVNT delivery compared with healthy subjects and heart failure patients.

• Brain activity shifted towards a calmer, more attentive mode - as measured by Alpha/Theta ratio in a study examining neurophysiological effects.

These investigations have also helped identify autonomic 'responders' - individuals who show greater HRV improvement - characterised by lower baseline vagal tone and higher sympathetic activity at rest, providing insight into which populations may derive the greatest autonomic benefit.

Selected Published Research Using Parasym Technology

Geng, Y., et al. (2022). Circadian stage-dependent and stimulation duration effects of transcutaneous auricular vagus nerve stimulation on heart rate variability. PLOS ONE.

Maestri, R., et al. (2024). Impact of optimised transcutaneous auricular vagus nerve stimulation on cardiac autonomic profile in healthy subjects and heart failure patients. Physiological Measurement.

Molaeizadeh, G., et al. (2025). Effects of transcutaneous vagus nerve stimulation, neurofeedback, and their combination on cortisol, anxiety, and depression subtypes in non-clinical adults.

5. Sleep and Physiological Recovery

This research area examines how AVNT stimulation may influence sleep quality and recovery-related physiological processes. Given that the parasympathetic nervous system plays a central role in facilitating restorative sleep states, and that many of the patient populations report sleep disruption as a primary symptom, sleep has become a meaningful secondary and primary outcome measure across several research domains.

Topics Explored

Key areas include: sleep quality as measured by validated instruments (Pittsburgh Sleep Quality Index, PSQI; actigraphy), night-time parasympathetic activation and its relationship to sleep architecture, the effect of autonomic dysregulation on sleep onset and maintenance, and the persistence of sleep improvements after intervention periods.

Clinical Studies

Sleep outcomes have been investigated in populations including individuals with fibromyalgia, Long COVID, chronic fatigue, and anxiety-related disorders. Studies have assessed changes in subjective sleep quality ratings and objective sleep metrics following courses of AVNT stimulation.

Key findings from this area of research include:

• ~29.6% reduction in PSQI sleep impairment scores - in fibromyalgia patients following four weeks of treatment.

• Sustained improvements in sleep quality - observed in Long COVID populations, with effects maintained beyond the active stimulation period.

• 31% improvement in validated sleep quality scores - in Long COVID and fibromyalgia populations compared with control groups.

These findings are notable because sleep disruption in chronic condition populations is frequently resistant to conventional interventions, and autonomic-based approaches that address the underlying nervous system dysregulation, rather than pharmacologically suppressing wakefulness, represent an area of growing scientific interest.

Selected Published Research Using Parasym Technology

Dolcini, J., et al. (2025). Vagal nerve stimulation and fibromyalgia: an additional therapeutic option. Clinical and Experimental Rheumatology.

Zheng, Y., et al. (2024). Transcutaneous vagus nerve stimulation improves Long COVID symptoms in a female cohort: a pilot study. Frontiers in Neurology.

6. Inflammation and Neuro-Immune Signalling

This domain examines how AVNT stimulation may influence inflammatory and immune signalling pathways. The 'inflammatory reflex' - the vagal arc through which the nervous system detects and modulates immune responses - is one of the most studied mechanisms in neuroimmunology, and Parasym’s research has contributed to understanding how non-invasive vagal activation may translate to measurable changes in inflammatory biomarkers.

Topics Explored

Key scientific concepts include: cytokine modulation (particularly TNF-alpha, IL-6, and other pro-inflammatory markers), oxidative stress pathways, immune cell signalling, neuro-immune communication via vagal afferents, and the cholinergic anti-inflammatory pathway.

Clinical Studies

Inflammatory research has been conducted in cardiovascular populations, particularly patients with acute heart failure and atrial fibrillation, as well as in chronic condition cohorts where systemic inflammation is understood to contribute to symptom burden. Studies have measured changes in serum inflammatory markers and cellular oxidative stress assays.

Key findings from this area of research include:

• 78% reduction in IL-6 (interleukin-6) - in patients with acute heart failure receiving low-level tragus stimulation, compared with a 9% reduction in the sham group.

• 28% reduction in endothelial oxidative stress markers - in the same study population, with no significant change observed in the sham arm.

• ~23% reduction in TNF-alpha - in patients with atrial fibrillation following six months of low-level tragus stimulation.

• Reductions in antiadrenergic autoantibodies and inflammatory cytokines - in POTS patients receiving active auricular VNS compared with sham.

These findings suggest that the anti-inflammatory effects of AVNT may extend beyond direct cardiovascular benefits, potentially contributing to systemic symptom reduction in populations where chronic low-grade inflammation plays a pathological role.

Selected Published Research Using Parasym Technology

Dasari, T., et al. (2023). Noninvasive low-level tragus stimulation attenuates inflammation and oxidative stress in acute heart failure. Clinical Autonomic Research.

Stavrakis, S., et al. (2020). TREAT AF. JACC: Clinical Electrophysiology.

Stavrakis, S., et al. (2023). Noninvasive vagus nerve stimulation in postural tachycardia syndrome. JACC: Clinical Electrophysiology.

7. Cognitive Function and Brain Performance

This research category explores how AVNT may influence cognitive performance, including memory recall, attention, processing speed, and executive function. The mechanistic basis draws on research showing that vagal afferent stimulation activates the locus coeruleus, the brain's principal noradrenergic nucleus, which plays a central role in attention, learning, and memory consolidation.

Topics Explored

Key areas include: immediate and delayed memory recall (assessed with validated tools), attention and inhibitory control, processing speed, working memory capacity, and neuroplasticity-related outcomes.

Clinical Studies

Cognitive investigations have been conducted in both healthy adult populations and clinical groups with neurological or post-viral conditions. Studies have assessed both short-term cognitive effects and longer-term changes following multi-week stimulation protocols.

Key findings from this area of research include:

• Significant improvements in immediate memory recall - in two independent studies using AVNT over two-to-four-week periods in community-dwelling adults.

• 19% improvement in attention and focus - in Long COVID patients after 10 days of treatment, with effect sizes in the medium-to-large range across attention, processing speed, episodic memory, and working memory, sustained at one month post-treatment.

The cognitive research domain is particularly relevant to populations experiencing neurological sequelae from viral illness, where autonomic dysfunction is believed to contribute to persistent cognitive impairment and brain fog.

Selected Published Research Using Parasym Technology

Cibulcova, M., et al. (2024). Influence of 2-week auricular transcutaneous vagus nerve stimulation on memory: findings from a randomized trial. Clinical Autonomic Research.

Jandackova, V.K., et al. (2023). The effect of long-term non-invasive vagus nerve stimulation on cognitive performance: results from a randomized placebo-controlled trial. Brain Stimulation.

Zheng, Y., et al. (2024). Transcutaneous vagus nerve stimulation improves Long COVID symptoms in a female cohort: a pilot study. Frontiers in Neurology.

Noé, E., et al. (2020). Feasibility, safety, and efficacy of transauricular vagus nerve stimulation in a cohort of patients with disorders of consciousness. Brain Stimulation.

8. Chronic Conditions and Autonomic Disorders

This research domain addresses complex systemic conditions characterised by autonomic dysregulation, including fibromyalgia, chronic fatigue syndrome (ME/CFS), and postural tachycardia syndrome (POTS). These conditions share common features of disrupted autonomic balance, persistent fatigue, pain sensitisation, and multi-system symptom burden that is poorly addressed by conventional pharmacological approaches. 

Topics Explored

Key areas include: widespread pain and central sensitisation, chronic fatigue and post-exertional malaise, autonomic dysfunction indices (COMPASS-31), fibromyalgia impact scores (FIQR, rFIQ), and the persistence of treatment effects following intervention periods.

Investigatory Clinical Studies

Studies in this domain have investigated auricular VNS in populations with diagnosed fibromyalgia, POTS, and related autonomic conditions. Researchers have measured changes in disease burden, pain intensity, autonomic function indices, and quality of life measures over treatment periods ranging from two to eight weeks.

Key findings from this area of research include:

• 37.8% reduction in Widespread Pain Index (WPI) - in fibromyalgia patients after four weeks of treatment, with effects persisting beyond the active treatment period.

• 38.7% reduction in overall fibromyalgia impact - as measured by the revised Fibromyalgia Impact Questionnaire, with chronic effects persisting four weeks after treatment ended.

• ~10% improvement in overall fibromyalgia disease burden - and ~12.7% reduction in autonomic dysfunction scores in a separate investigation.

• 40% reduction in postural tachycardia - in POTS patients, with concurrent reductions in autoantibodies and inflammatory markers.

The observation that treatment effects persist after active stimulation has ended is scientifically significant. It suggests that AVNT may produce lasting changes in autonomic regulatory set-points, rather than simply providing symptomatic relief during active use.

Selected Published Research Using Parasym Technology

Dolcini, J., et al. (2025). Vagal nerve stimulation and fibromyalgia: an additional therapeutic option. Clinical and Experimental Rheumatology.

Lommano, C., et al. (2026). Non-invasive auricular vagus nerve stimulation in fibromyalgia: impacts on autonomic function, central sensitisation and pain catastrophizing.

Stavrakis, S., et al. (2023). Noninvasive vagus nerve stimulation in postural tachycardia syndrome. JACC: Clinical Electrophysiology.

Ongoing Scientific Investigation

The clinical science underpinning AVNT continues to evolve. Parasym's research programme is active and expanding, with ongoing work exploring new physiological applications for the technology, deeper mechanistic investigation of vagal pathways, refinements to stimulation protocols, and research into previously understudied populations and clinical contexts.

Areas of emerging investigation include the optimisation of stimulation dosing (frequency, duration, timing), the identification of predictive biomarkers for treatment response, gut-brain axis modulation, neuroinflammation, applications in burnout and Long COVID recovery, ADHD-related attention regulation, hormonal health, athletic performance recovery, and the long-term safety profile of sustained use of the technology in diverse clinical populations.

As the field of non-invasive neuromodulation matures, the depth and independence of Parasym's research programme position the company at the frontier of evidence-based auricular VNS - building a scientific legacy that extends beyond any single product, and contributing to the broader understanding of how vagal activation can support human health.

The Future of Auricular Vagus Nerve Therapy Research

AVNT occupies a unique position in modern neuroscience and clinical medicine. It bridges the gap between invasive neuromodulation - with its well-established but surgically limited applications - and the emerging consumer wellness category, where devices often lack rigorous scientific validation.

Parasym's research programme is helping to define what evidence-based, non-invasive neuromodulation looks like at scale. By investing in institution-partnered, peer-reviewed clinical research across multiple physiological domains and patient populations, Parasym has built a scientific foundation that continues to inform both the development of its technology and the broader understanding of how the vagus nerve can be engaged to support human well-being.

The Nurosym device represents the current consumer expression of this scientific work, bringing a decade of AVNT research into a format designed for consistent, daily, at-home use. As the research programme continues to grow, so too does the evidence base that underpins it.

For individuals seeking evidence-aligned approaches to nervous system support, the depth of Parasym's clinical research offers a meaningful point of differentiation, not a promise of guaranteed outcomes, but a transparent, scientifically rigorous account of what auricular vagus nerve stimulation has been studied to do, and how.

Disclaimer: *Nurosym is a CE-marked medical device in Europe. The clinical research referenced in this article was conducted using Parasym’s neuromodulation technology under research conditions, some of which include populations outside of the device’s primary indication. Individual results may vary. All percentage figures cited reflect findings from specific study populations and should not be interpreted as a medical claim and cannot guarantee outcomes for all users. Individuals should consult a qualified healthcare professional regarding their personal health needs.

 

Zurück zum Blog